<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01779401</url>
  </required_header>
  <id_info>
    <org_study_id>2011-4003-03</org_study_id>
    <nct_id>NCT01779401</nct_id>
  </id_info>
  <brief_title>Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients</brief_title>
  <acronym>CREATIVE</acronym>
  <official_title>Investigator Initiated Prospective Study to Investigate the Best Anti-platelet Treatment in High Thrombotic Risk PCI Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Municipal Health Bureau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haemonetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To identify the high-risk patients who might have in-stent thrombosis after PCI with
      thromboelastography and to head-to-head compare two intensified antiplatelet therapeutic
      strategies of double-dosage Clopidogrel and triple antiplatelet therapy with Cilostazol with
      the standard antiplatelet therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study population: Age 18 - 75, male or non-pregnant female; stable or unstable angina with
      evidence of myocardial ischemia, or patient with myocardial infarction; coronary angiography
      reveals stenosis lesions; discovery of ADP induced platelet inhibition rate &lt; 50% and MAADP &gt;
      47mm via thromboelastography (indicating low responsiveness to Clopidogrel with high risk for
      stent thrombosis formation); is able to understand the objective of the trial, takes part
      voluntarily and signs the written informed consent form.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiac and cerebrovascular events</measure>
    <time_frame>within 1.5years of patient enrolled</time_frame>
    <description>MACCE, including cardiac death, myocardial infarction, target vessel revascularization and cerebrovascular events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoint</measure>
    <time_frame>within 1.5 years of patients enrolled</time_frame>
    <description>Occurrence of stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding</measure>
    <time_frame>within 1.5 years of patients' enrolled</time_frame>
    <description>Major bleeding and minor bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life of patient</measure>
    <time_frame>within 1.5 years of patients' enrolled</time_frame>
    <description>to evaluate with Seattle Angina Scale</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1078</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Clopidogrel + Aspirit</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A Standard antiplatelet therapy control group： Clopidogrel 75mg Qd + Aspirin 100mg Qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel + Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>B Double-dosage Clopidogrel group： Clopidogrel 150mg Qd + Aspirin 100mg Qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel + Aspirin + Cilostazol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>C triple antiplatelet therapy group： Cilostazol 100mg Bid + Aspirin 100mg Qd + Clopidogrel 75mg Qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel 75mg</intervention_name>
    <arm_group_label>Clopidogrel + Aspirit</arm_group_label>
    <arm_group_label>Clopidogrel + Aspirin + Cilostazol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel 150mg</intervention_name>
    <arm_group_label>Clopidogrel + Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 100mg</intervention_name>
    <arm_group_label>Clopidogrel + Aspirit</arm_group_label>
    <arm_group_label>Clopidogrel + Aspirin</arm_group_label>
    <arm_group_label>Clopidogrel + Aspirin + Cilostazol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol 100mg</intervention_name>
    <arm_group_label>Clopidogrel + Aspirin + Cilostazol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 - 75, male or non-pregnant female;

          2. Stable or unstable angina with evidence of myocardial ischemia, or patient with
             myocardial infarction;

          3. Coronary angiography reveals stenosis lesions;

          4. Discovery of ADP induced platelet inhibition rate &lt; 50% and MAADP &gt;47mm via
             thromboelastography (indicating low responsiveness to Clopidogrel with high risk for
             stent thrombosis formation);

          5. Is able to understand the objective of the trial, takes part voluntarily and signs the
             written informed consent form.

        Exclusion Criteria:

          1. Those who have participated in other drug or therapy equipment clinical trials but did
             not reach the main study endpoint time limit;

          2. Symptoms of severe heart failure (NYHA Class III and above) or left ventricular
             ejection fraction &lt; 40% (ultrasound or left ventricle ngiography);

          3. Pregnant or lactating women;

          4. severely impaired renal function before surgery: serum creatinine &gt; 2.0mg/dl;

          5. Impaired liver function before surgery: Serum GPT &gt; 120U/L;

          6. Bleeding tendency, history of active peptic ulcer, history of cerebral hemorrhage or
             cavum subarachnoidale bleeding, patients with antiplatelet agent and anticoagulant
             treatment contraindications and hence are unable to undergo anticoagulant therapy;

          7. Patients who are unable to withstand dual antiplatelet therapy due to allergy to
             Aspirin, Clopidogrel or ticlopidine, heparin, contrast agent, paclitaxel and metals;

          8. Leucocyte &lt; 3.5 x 109; and/or platelet &lt; 100,000/mm3 or &gt; 750,000/mm3;

          9. Patient's life expectancy is less than 12 months;

         10. Patients who plan to undergo coronary artery bypass grafting or other surgery within 1
             year;

         11. Those waiting for heart transplant;

         12. Patients who are deemed by the researchers to have low compliance and unable to abide
             by the requirements and complete the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuejin Yang, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Fuwai Hospital, CAMS &amp; PUMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fuwai Cardiovascular Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fuwai Cardiovascular Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2013</study_first_submitted>
  <study_first_submitted_qc>January 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2013</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>Yi-Da Tang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>PCI</keyword>
  <keyword>platelet function monitoring</keyword>
  <keyword>Thrombelastography</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>cilostazol</keyword>
  <keyword>in-stent thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

